339TiP Phase III study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (CRT) in primary unresected patients with locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) in Asia: LUX-Head & Neck 4 (LUX-H&N4)
Year: 2015
Type: article
Study design: Study Protocol
Source: Annals of Oncology
Institutions: Fudan University, Fudan University Shanghai Cancer Center, Chinese University of Hong Kong, Chinese Academy of Medical Sciences & Peking Union Medical College, Samsung Medical Center, Sungkyunkwan University, Moores Cancer Center, National Cancer Centre Singapore, Jilin Province Tumor Hospital, Zhejiang Cancer Hospital, Asan Medical Center, University of Ulsan, Sichuan University, West China Hospital of Sichuan University, Peking University Cancer Hospital, Boehringer Ingelheim (China), Boehringer Ingelheim (Denmark), Chang Gung Memorial Hospital, Keelung Chang Gung Memorial Hospital
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2419070556